CHEK2 and lung carcinoma: Overall, 1267 lung cancer cases were retrieved from TCGA which revealed a higher relative prevalence of EGFR (n = 30, 22.9% vs n = 148, 11.7%, P = 0.001) and CHEK2 (n = 11, 8.4% vs n = 20, 1.6%, P = 0.000001) mutations in the Northern England population.